Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:05 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Terminated Phase 2 Interventional

Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

NCT05212818
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
TF0023
Drug
Lead sponsor
Techfields Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Gaithersburg, Maryland • Teaneck, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 3 Interventional

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
83
States / cities
Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

NCT05091723
View directory record Official record
Conditions
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
Interventions
Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 1 Interventional

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

NCT00623259
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-mBN120B
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2010 · Synced Nov 1, 2026, 9:05 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities

NCT06428643
View directory record Official record
Conditions
Chlamydia, Gonorrhea, Hiv, Syphilis
Interventions
Chlamydia, gonorrhea, syphilis, and HIV screening
Other
Lead sponsor
Tulane University
Other
Eligibility
15 Years to 26 Years
Enrollment
2,322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Chronic Hepatitis Intervention Project for Drug Users

NCT00596843
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
Motivational interviewing, Educational intervention
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 1, 2026, 9:05 PM EST
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 1, 2026, 9:05 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Conversations You Want About Corona Virus Disease (COVID-19)

NCT05191420
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 1, 2026, 9:05 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola

NCT05909176
View directory record Official record
Conditions
Preexposure Prophylaxis, HIV Infections
Interventions
GYN Residency Training, Social Media Campaign
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 1, 2026, 9:05 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

The DC Cohort Longitudinal HIV Status Neutral Study

NCT01206920
View directory record Official record
Conditions
HIV, AIDS
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
Not listed
Enrollment
19,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2041
U.S. locations
14
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 1, 2026, 9:05 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Text-based Reminders to Promote COVID-19 Vaccinations

NCT04801524
View directory record Official record
Conditions
Covid19, Vaccines
Interventions
Self-benefit, Prosocial-benefit, Early access, Fresh start
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
250,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Nov 1, 2026, 9:05 PM EST
Completed No phase listed Observational

Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children

NCT00001435
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Depressive Disorder, HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 3 Interventional

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Lamivudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

H5 Booster After a Two Dose Schedule

NCT00240968
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

NCT06020118
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Years to 64 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Nov 1, 2026, 9:05 PM EST
Completed Not applicable Interventional

Multimodal Investigation of Post COVID-19 in Females

NCT05225220
View directory record Official record
Conditions
Post COVID-19, Cognitive Dysfunction
Interventions
Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Nov 1, 2026, 9:05 PM EST
Completed Not applicable Interventional

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

NCT00000635
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Trifluridine, Bacitracin zinc/Polymyxin B sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 1, 2026, 9:05 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

NCT00142740
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Nov 1, 2026, 9:05 PM EST
Completed Not applicable Interventional

A Commitment Device for Medication Adherence Among HIV Patients

NCT01455740
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV
Interventions
Provider Visit Incentive (PVI), Incentive Choice (IC)
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Nov 1, 2026, 9:05 PM EST
Terminated Phase 3 Interventional Results available

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

NCT01446250
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Beverly Hills, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Nov 1, 2026, 9:05 PM EST
Completed Phase 1 Interventional

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

NCT00000391
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide T
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Nov 1, 2026, 9:05 PM EST